Natera Inc (NTRA) Insider Matthew Rabinowitz Sells 5,672 Shares

Share on StockTwits

Natera Inc (NASDAQ:NTRA) insider Matthew Rabinowitz sold 5,672 shares of Natera stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $16.00, for a total transaction of $90,752.00. Following the completion of the sale, the insider now owns 1,288,853 shares in the company, valued at $20,621,648. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Natera stock traded down $0.25 during trading hours on Friday, hitting $18.67. 7,546 shares of the company traded hands, compared to its average volume of 610,960. The stock has a market cap of $1.03 billion, a price-to-earnings ratio of -8.83 and a beta of 1.84. The company has a current ratio of 2.44, a quick ratio of 2.32 and a debt-to-equity ratio of 1.30. Natera Inc has a 1-year low of $8.60 and a 1-year high of $29.62.

Natera (NASDAQ:NTRA) last released its earnings results on Tuesday, March 12th. The medical research company reported ($0.51) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.51). The firm had revenue of $67.00 million for the quarter, compared to analysts’ expectations of $62.87 million. Natera had a negative net margin of 49.72% and a negative return on equity of 1,214.02%. Research analysts expect that Natera Inc will post -1.59 earnings per share for the current fiscal year.

Several analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Natera from a “sell” rating to a “hold” rating in a research report on Friday. ValuEngine downgraded shares of Natera from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, January 9th. Finally, BidaskClub downgraded shares of Natera from a “sell” rating to a “strong sell” rating in a research report on Friday, March 1st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $27.75.

A number of institutional investors have recently added to or reduced their stakes in NTRA. Great West Life Assurance Co. Can increased its stake in Natera by 136.8% during the 4th quarter. Great West Life Assurance Co. Can now owns 5,920 shares of the medical research company’s stock valued at $80,000 after buying an additional 3,420 shares during the period. Legal & General Group Plc increased its stake in Natera by 14.5% during the 4th quarter. Legal & General Group Plc now owns 5,826 shares of the medical research company’s stock valued at $81,000 after buying an additional 736 shares during the period. Pacer Advisors Inc. acquired a new position in Natera during the 3rd quarter valued at about $106,000. Point72 Hong Kong Ltd acquired a new position in Natera during the 3rd quarter valued at about $119,000. Finally, Quantbot Technologies LP acquired a new position in Natera during the 3rd quarter valued at about $135,000. 90.05% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Natera Inc (NTRA) Insider Matthew Rabinowitz Sells 5,672 Shares” was published by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.tickerreport.com/banking-finance/4223552/natera-inc-ntra-insider-matthew-rabinowitz-sells-5672-shares.html.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

See Also: Is the Dow Jones Industrial Average (DJIA) still relevant?

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Natera Inc  Insider Matthew Rabinowitz Sells 5,672 Shares
Natera Inc Insider Matthew Rabinowitz Sells 5,672 Shares
Geoffrey Wilson Purchases 19,812 Shares of Wam Global Ltd  Stock
Geoffrey Wilson Purchases 19,812 Shares of Wam Global Ltd Stock
Traders Sell Oracle  on Strength
Traders Sell Oracle on Strength
New Home Company Inc  Director Acquires $35,550.00 in Stock
New Home Company Inc Director Acquires $35,550.00 in Stock
Insider Buying: Diebold Nixdorf Inc  Director Buys 2,500 Shares of Stock
Insider Buying: Diebold Nixdorf Inc Director Buys 2,500 Shares of Stock
$149.01 Million in Sales Expected for Taubman Centers, Inc.  This Quarter
$149.01 Million in Sales Expected for Taubman Centers, Inc. This Quarter


Leave a Reply

© 2006-2019 Ticker Report